The Study of ICP-248 in Patients With Mature B-cell Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

191

Participants

Timeline

Start Date

March 9, 2023

Primary Completion Date

August 30, 2025

Study Completion Date

October 30, 2026

Conditions
Hematological Malignancies
Interventions
DRUG

ICP-248

Eligible patients will receive ICP-248 orally as per the protocol, once daily for every 28 days as one treatment cycle (except for the food effect investigation phase), until progressive disease (PD), intolerable toxicity, withdrawal of consent, loss to follow-up, initiation of other anti-cancer therapy, death, or end of study, whichever occurs first.

DRUG

ICP-248

Eligible patients will receive ICP-248 orally as specified in the treatment arm.

DRUG

ICP-248+Orelabrutinib

Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.

DRUG

ICP-248+Orelabrutinib

Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.

DRUG

ICP-248 +Rituximab

Eligible patients will receive ICP-248 and Rituximab as specified in the treatment arm.

DRUG

ICP-248+Orelabrutinib

Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.

DRUG

ICP-248+Orelabrutinib+Rituximab

Eligible patients will receive ICP-248 and Orelabrutinib and Rituximab as specified in the treatment arm.

Trial Locations (22)

100191

RECRUITING

Peking University Third Hospital, Beijing

110022

RECRUITING

Shenyang Hospital Of China Medical University, Shenyang

116027

RECRUITING

The Second Hospital of Dalian Medical University, Dalian

200025

RECRUITING

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

210029

RECRUITING

Jiangsu Province Hospital, Nanjing

230022

RECRUITING

The First Affiliated Hospital of Anhui Medical University, Hefei

233099

RECRUITING

The First Affiliated Hospital of Bengbu Medical College, Bengbu

250117

RECRUITING

Shandong cancer hospital, Jinan

310000

RECRUITING

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

330000

RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

330029

RECRUITING

Jiangxi Cancer Hospital, Nanchang

350001

RECRUITING

Fujian Medical University Union Hospital, Fuzhou

361003

RECRUITING

The First Affiliated Hospital of Xiamen University, Xiamen

400016

RECRUITING

The First Affiliated Hospital of Chongqing Medical University, Chongqing

410000

RECRUITING

Hunan Cancer Hospital, Changsha

430014

RECRUITING

The Central Hospital of Wuhan, Wuhan

430022

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

450008

RECRUITING

Henan Cancer Hospital, Zhengzhou

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

510062

RECRUITING

Sun Yat-Sen University Cancer Center, Guangzhou

610000

RECRUITING

West China Hospital of Sichuan University, Chengdu

Unknown

RECRUITING

Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Beijing InnoCare Pharma Tech Co., Ltd.

INDUSTRY